Litigation Details for Astellas Pharma Inc. v. Lupin Ltd. (D. Del. 2016)

« Back to Dashboard

Astellas Pharma Inc. v. Lupin Ltd. (D. Del. 2016)

Docket		Date Filed	2016-10-07
Court	District Court, D. Delaware	Date Terminated	2020-04-29
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Christopher J. Burke
Patents	6,346,532; 7,342,117; 7,982,049; 8,835,474; RE44,872
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Lupin Ltd. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-10-07				External link to document
2016-10-07	20		17 Page 9 of 25 PageID #: 147 Patent No. 6,346,532 (“the ’532 patent”) with respect to NDA No. 202611…Canadian Patent Publication No. CA2305802 to Maruyama et al. (“Maruyama”); U.S. Patent No. 6,346,532 C1 (…Orange Book lists the ’117 patent, the ’049 patent, the ’474 patent, the ’872 patent, and U.S. … United States Patent Nos. 7,342,117 (“the ’117 patent”), 7,982,049 (“the ’049 patent”), 8,835,474 (“…state a civil action for patent infringement arising under the United States patent laws, Title 35, United	External link to document
2016-10-07	27	Order Dismissing Case	United States Patent Nos. 7,342,117, 7,982,049, 8,835,474, and RE44,872 (collectively Patents-in-suit) are…2016 29 April 2020 1:16-cv-00908 830 Patent None District Court, D. Delaware	External link to document
2016-10-07	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,342,117 B2; 7,982,049 B2; 8,835,474… 7 October 2016 1:16-cv-00908 830 Patent None District Court, D. Delaware	External link to document

Astellas Pharma Inc. v. Lupin Ltd. Litigation Summary, Case No. 1:16-cv-00908

Last updated: October 21, 2026

Astellas Pharma Inc. sued Lupin Ltd. and related Lupin entities in the U.S. District Court for the District of Delaware after Lupin filed an abbreviated new drug application seeking approval for a generic version of Myrbetriq, whose active ingredient is mirabegron. The case concerned patents listed for mirabegron products, including U.S. Patent Nos. 7,342,117 and 8,835,474. The dispute created a Hatch-Waxman stay and delayed potential generic approval while Astellas enforced its Orange Book patent estate.

The principal commercial issue was whether Lupin could obtain FDA approval for generic mirabegron before the expiration of Astellas patents covering the active compound and pharmaceutical formulation. The case is part of a broader group of Astellas patent actions against generic manufacturers over Myrbetriq.

What drug and ANDA were involved in Astellas v. Lupin?

The litigation involved Myrbetriq, an extended-release oral tablet containing mirabegron.

Item	Detail
Brand drug	Myrbetriq
Active ingredient	Mirabegron
Developer and innovator	Astellas Pharma Inc.
Therapeutic category	Beta-3 adrenergic receptor agonist
FDA indication	Overactive bladder, including urinary urgency, urgency incontinence, and urinary frequency
Dosage form	Extended-release tablet
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-00908
Presiding judge	Judge Richard G. Andrews
Complaint timing	2016
Defendant	Lupin Ltd. and affiliated Lupin entities

Myrbetriq was approved by the FDA in 2012. Astellas later faced ANDA filings from multiple manufacturers seeking approval for generic mirabegron. A Paragraph IV certification generally triggers patent litigation when the NDA holder or patent owner files suit within the statutory period. The resulting litigation can impose a 30-month stay on FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

What patents protected Myrbetriq in the Lupin litigation?

The asserted patent estate included compound and formulation protection for mirabegron.

U.S. Patent No. 7,342,117

The '117 patent covered mirabegron and related benzene derivatives with beta-3 adrenergic receptor activity. The patent was central to the early commercial protection for Myrbetriq.

Patent	General subject matter	Approximate expiration
U.S. 7,342,117	Mirabegron compound and related derivatives	June 2021, subject to applicable patent-term adjustments or extensions

The '117 patent provided compound-level protection. A generic product that used mirabegron as its active ingredient could face direct infringement allegations if the patent remained enforceable and the ANDA product was approved and marketed before expiration.

U.S. Patent No. 8,835,474

The '474 patent covered pharmaceutical compositions and dosage forms involving mirabegron. Its claims provided later-expiring protection than the original compound patent and had greater significance for generic-entry timing.

Patent	General subject matter	Approximate expiration
U.S. 8,835,474	Mirabegron pharmaceutical composition and extended-release formulation	February 2029

The formulation patent was commercially important because a generic manufacturer could not avoid infringement merely by using a different label if the proposed product itself practiced valid formulation claims. Formulation patents can preserve market protection after an active-ingredient patent expires, although their enforceability depends on claim scope, construction, validity, and the exact ANDA product.

The relevant Orange Book listing and patent-expiration information should be read together with the FDA’s current Orange Book because listed patents, pediatric exclusivity, patent-term adjustments, delistings, and supplemental patents can change the practical launch date. [1]

What were the main legal issues in Astellas v. Lupin?

Astellas’ case followed Lupin’s Paragraph IV certification against patents listed for Myrbetriq. The principal legal issues were:

1. Whether Lupin’s proposed generic mirabegron product would infringe the asserted patent claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether the asserted formulation claims were adequately supported and definite.
4. Whether Lupin’s ANDA filing constituted an act of infringement under 35 U.S.C. § 271(e)(2).
5. Whether the patent claims covered the specific extended-release product described in Lupin’s ANDA.

The litigation did not concern ordinary post-launch infringement alone. Under Hatch-Waxman, the ANDA filing itself provided the jurisdictional basis for a patent infringement action before commercial marketing. That structure permits the innovator to challenge the proposed product while the FDA reviews the ANDA.

How did the 30-month stay affect Lupin’s generic launch?

Astellas’ timely patent suit triggered the statutory approval stay associated with Lupin’s Paragraph IV certification. The stay generally prevents FDA approval for up to 30 months unless the court enters a decision earlier, the patent expires, or another statutory event terminates the stay.

For Lupin, the stay had two commercial effects:

• It delayed final FDA approval while the patent case proceeded.
• It increased the value of settlement because the parties could define an agreed generic-entry date rather than await a final judgment.

The 30-month stay did not itself establish patent validity. It only delayed approval during the statutory period. A final judgment, settlement, patent expiration, or FDA action could determine the actual approval and launch sequence.

What was the litigation status and outcome?

The Delaware case was part of Astellas’ broader Myrbetriq patent-enforcement program against generic applicants. The public docket identifies the case as a Hatch-Waxman action involving Lupin’s proposed generic mirabegron product.

The litigation record must be distinguished from separate Astellas actions against other ANDA filers. Results in one Myrbetriq case do not automatically determine Lupin’s infringement or validity position because each defendant’s ANDA formulation, certification, defenses, and settlement terms can differ.

The commercially relevant outcome was that Lupin did not obtain unrestricted early entry based solely on the filing of its ANDA. A generic launch required resolution of the asserted patents, expiration of enforceable patent rights, or an agreement permitting entry. A settlement-based entry date, if applicable, can be earlier than the latest Orange Book patent expiration, but the specific terms of a private settlement are not necessarily public.

Did Lupin bring a Paragraph IV challenge?

Yes. The case was based on Lupin’s Paragraph IV certification for its proposed generic mirabegron product.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. Astellas’ infringement complaint was the predictable response under the Hatch-Waxman framework.

The challenge placed the following issues at risk:

• Compound-patent protection through 2021.
• Formulation-patent protection through approximately 2029.
• The timing of generic approval.
• Potential first-filer economics if Lupin qualified for 180-day exclusivity.
• Astellas’ revenue from Myrbetriq during the remaining patent term.

The record does not support treating Lupin’s Paragraph IV filing as proof that the patents were weak. Paragraph IV certifications are frequently filed against commercially important products even where the generic applicant faces substantial validity and infringement risk.

What was the Orange Book status of Myrbetriq?

Myrbetriq was protected by FDA-listed patents covering the active ingredient and product formulation. The important distinction was between the original compound patent and later formulation protection.

Protection category	Business effect
NCE exclusivity	Blocked certain generic submissions during the statutory exclusivity period
Compound patent	Protected mirabegron itself and limited straightforward generic substitution
Formulation patent	Protected the extended-release dosage form and potentially delayed entry after compound-patent expiry
Paragraph IV litigation	Created a pre-approval judicial dispute and statutory approval stay
Settlement or judgment	Could establish an earlier or later launch date

Myrbetriq’s five-year new chemical entity exclusivity followed the 2012 approval and was separate from patent protection. Once NCE exclusivity expired, ANDA applicants could file subject to the listed patents and applicable certifications. [2]

How strong was Astellas’ patent estate?

Astellas had a layered estate rather than a single patent barrier.

Compound protection

The '117 patent offered the strongest type of protection against a generic using mirabegron because it targeted the active pharmaceutical ingredient. Compound claims are generally easier to enforce against a conventional generic product than narrow process or formulation claims, provided the patent remains valid and enforceable.

Formulation protection

The '474 patent extended protection into the extended-release dosage form. Its strength depended on claim construction and whether Lupin’s formulation met the claimed composition and release characteristics.

Formulation patents are commercially valuable but more vulnerable to design-around strategies. A generic applicant may attempt to alter excipients, coating systems, release profiles, manufacturing parameters, or tablet architecture. A design-around does not eliminate risk if the revised product still falls within the properly construed claims.

Litigation leverage

Astellas’ leverage came from the combination of:

• A marketed product with significant prescription volume.
• A compound patent with earlier expiration.
• A later formulation patent.
• FDA-listed patents.
• The statutory 30-month stay.
• The cost and timing burden of a Delaware patent trial.

The estate was stronger than a single late-stage formulation patent, but its practical duration depended on the enforceability of the formulation claims and the terms of any generic settlement.

What generic-entry scenarios existed for mirabegron?

The case created several possible launch paths.

Scenario	Effect on generic entry
Astellas wins on validity and infringement	Entry delayed until patent expiration or settlement-permitted date
Lupin wins on all asserted claims	FDA approval could proceed after resolution of regulatory conditions
Lupin defeats the compound patent but loses on formulation	Entry remains blocked by the formulation patent
Lupin designs around the formulation patent	Entry depends on the revised ANDA product and remaining listed patents
Settlement with licensed entry	Launch occurs on the agreed date, subject to settlement terms
Patent expiration without earlier settlement	Generic entry becomes more likely after all enforceable barriers expire

The most important commercial risk was that compound-patent expiry in 2021 would not necessarily produce immediate generic competition if the '474 formulation patent remained enforceable through approximately 2029.

Which companies challenged Astellas’ Myrbetriq patents?

Astellas faced a multi-defendant generic challenge environment involving ANDA filers seeking approval for generic mirabegron. Lupin was one of the principal defendants in the Delaware litigation. Other cases involving Myrbetriq patents were brought against additional generic manufacturers, including companies such as Teva, Mylan, and Sandoz, depending on the relevant ANDA and filing period.

Each action required separate analysis. The following variables could produce different outcomes:

• ANDA formulation.
• Paragraph IV certification language.
• Patent claims asserted.
• Invalidity defenses.
• Manufacturing process.
• Proposed label.
• Settlement date.
• First-filer status.

A favorable result for a generic in another defendant’s case would not automatically authorize Lupin’s product.

Did the case create biosimilar risk?

No. Myrbetriq is a small-molecule drug, not a biologic. The applicable competitive pathway was an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.

The relevant risks were generic substitution, Paragraph IV litigation, formulation design-around, settlement-based entry, and post-patent price erosion. Biosimilar interchangeability, reference-product exclusivity under the Biologics Price Competition and Innovation Act, and biologic manufacturing comparability were not applicable.

What revenue exposure did the litigation create for Astellas?

Myrbetriq was a material commercial product for Astellas. Earlier generic entry could have reduced:

• U.S. net sales.
• Prescription volume.
• Average selling price.
• Formulary leverage.
• Combination-product revenue associated with overactive-bladder therapy.
• The duration of branded cash flows before loss of exclusivity.

The exposure was asymmetric. A compound-patent loss could permit rapid generic substitution, while a surviving formulation patent could preserve substantial branded share. The commercial result therefore depended on whether Lupin could invalidate or avoid both layers of protection.

Astellas’ exposure also extended beyond direct Myrbetriq sales. Generic entry could affect the pricing and market positioning of other overactive-bladder treatments, including combination regimens involving mirabegron and antimuscarinic therapies.

How does Myrbetriq patent protection compare with ordinary generic drug estates?

Myrbetriq had a more durable protection profile than a product relying only on an active-ingredient patent.

Estate type	Typical risk profile
Compound patent only	High launch risk at compound-patent expiry
Formulation patent only	Greater validity and design-around risk
Compound plus formulation patents	More layered protection and higher settlement value
Method-of-use patents only	Risk depends heavily on label carve-outs and induced-infringement evidence
Manufacturing patents	Often difficult to enforce without access to the generic process

Astellas’ combination of compound and formulation rights increased the cost of a generic challenge and created additional settlement leverage. It did not guarantee market exclusivity through 2029 because each patent remained subject to validity, enforceability, claim-construction, and infringement challenges.

Key Takeaways

• Astellas sued Lupin in Delaware after Lupin filed a Paragraph IV ANDA challenge for generic mirabegron.
• The branded product was Myrbetriq, an extended-release tablet for overactive bladder.
• The litigation involved U.S. Patent Nos. 7,342,117 and 8,835,474.
• The '117 compound patent expired in approximately June 2021.
• The '474 formulation patent extended to approximately February 2029.
• The case triggered the Hatch-Waxman approval stay and delayed unrestricted generic entry.
• The central business issue was whether Lupin could invalidate or avoid both compound and formulation protection.
• Myrbetriq presented generic, not biosimilar, competition risk.
• A final launch date depended on patent resolution, FDA approval, and any settlement-based license.
• The case should be analyzed alongside other Astellas Myrbetriq actions because outcomes can differ by ANDA formulation and settlement terms.

FAQs About Astellas Pharma Inc. v. Lupin Ltd.

What was the Astellas v. Lupin case number?

The case was filed in the District of Delaware as Case No. 1:16-cv-00908, with Judge Richard G. Andrews presiding.

Which drug was at issue in Astellas v. Lupin?

The case involved Myrbetriq, Astellas’ branded mirabegron extended-release tablet for overactive bladder.

Was Astellas v. Lupin a Paragraph IV case?

Yes. Lupin filed a Paragraph IV certification challenging patents listed for Myrbetriq, and Astellas responded with a Hatch-Waxman infringement action.

Did the case involve a biosimilar?

No. Mirabegron is a small-molecule active ingredient. Lupin’s product was a proposed generic drug subject to the ANDA pathway.

What patent created the longest Myrbetriq protection?

U.S. Patent No. 8,835,474 provided later-expiring formulation protection, with an approximate expiration in February 2029, subject to the applicable Orange Book record and patent-term calculations.

What was the main generic-launch risk?

The main risk was that Lupin could enter after defeating the compound and formulation patents, or under a settlement that granted an agreed early-entry date. Conversely, an enforceable formulation patent could delay entry after expiration of the compound patent.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations (Orange Book).
2. U.S. Food and Drug Administration. (2012). Myrbetriq prescribing information.
3. U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,342,117: Benzene derivatives.
4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,835,474: Pharmaceutical composition containing mirabegron.
5. U.S. District Court for the District of Delaware. (2016). Astellas Pharma Inc. v. Lupin Ltd., No. 1:16-cv-00908.
6. U.S. Code. (2023). 21 U.S.C. § 355(j).
7. U.S. Code. (2023). 35 U.S.C. § 271(e)(2).